The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Paolo A. Ascierto; Paolo Bruzzi; Alexander Eggermont; Omid Hamid; Hussein A. Tawbi; Alexander Van Akkooi; Alessandro Testori; Corrado Caracò; Igor Puzanov; Francesco Perrone

doi:10.1186/s12967-019-1892-5

The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Paolo A. Ascierto
, Paolo Bruzzi
, Alexander Eggermont
, Omid Hamid
, Hussein A. Tawbi
, Alexander Van Akkooi
, Alessandro Testori
, Corrado Caracò
, Igor Puzanov
, Francesco Perrone

Medicine

IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
Ospedale Policlino San Martino -University of Genoa
Institut Gustave Roussy
The Angeles Clinic and Research Institute
University of Texas MD Anderson Cancer Center
Antoni van Leeuwenhoek Hospital
European Organisation for Research and Treatment of Cancer Data Center

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

Original language	English
Article number	148
Journal	Journal of Translational Medicine
Volume	17
Issue number	1
DOIs	https://doi.org/10.1186/s12967-019-1892-5
State	Published - May 10 2019

Keywords

Adjuvant
Anti-CTLA-4
Anti-PD-1
BRAF inhibitor
Immunotherapy
MEK inhibitor
Melanoma
Neoadjuvant
Targeted therapy

Access to Document

10.1186/s12967-019-1892-5

Cite this

@article{d1da4f8e734949e7b229c23a38b201aa,

title = "The great debate at {"}melanoma Bridge 2018{"}, Naples, December 1st, 2018",

abstract = "The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.",

keywords = "Adjuvant, Anti-CTLA-4, Anti-PD-1, BRAF inhibitor, Immunotherapy, MEK inhibitor, Melanoma, Neoadjuvant, Targeted therapy",

author = "Ascierto, \{Paolo A.\} and Paolo Bruzzi and Alexander Eggermont and Omid Hamid and Tawbi, \{Hussein A.\} and \{Van Akkooi\}, Alexander and Alessandro Testori and Corrado Carac{\`o} and Igor Puzanov and Francesco Perrone",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = may,

day = "10",

doi = "10.1186/s12967-019-1892-5",

language = "English",

volume = "17",

journal = "Journal of Translational Medicine",

issn = "1479-5876",

publisher = "BioMed Central Ltd",

number = "1",

}

TY - JOUR

T1 - The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

AU - Ascierto, Paolo A.

AU - Bruzzi, Paolo

AU - Eggermont, Alexander

AU - Hamid, Omid

AU - Tawbi, Hussein A.

AU - Van Akkooi, Alexander

AU - Testori, Alessandro

AU - Caracò, Corrado

AU - Puzanov, Igor

AU - Perrone, Francesco

PY - 2019/5/10

Y1 - 2019/5/10

N2 - The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

AB - The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

KW - Adjuvant

KW - Anti-CTLA-4

KW - Anti-PD-1

KW - BRAF inhibitor

KW - Immunotherapy

KW - MEK inhibitor

KW - Melanoma

KW - Neoadjuvant

KW - Targeted therapy

UR - https://www.scopus.com/pages/publications/85065589434

U2 - 10.1186/s12967-019-1892-5

DO - 10.1186/s12967-019-1892-5

M3 - Article

C2 - 31077205

AN - SCOPUS:85065589434

SN - 1479-5876

VL - 17

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

IS - 1

M1 - 148

ER -

The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this